Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

NCT04047641 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia
Blasts 20 Percent or More of Bone Marrow Nucleated Cells
High Risk Myelodysplastic Syndrome
Recurrent Acute Biphenotypic Leukemia
Recurrent Acute Myeloid Leukemia
Recurrent High Risk Myelodysplastic Syndrome
Refractory Acute Myeloid Leukemia
Refractory High Risk Myelodysplastic Syndrome

Interventions

DRUG: Cladribine
DRUG: Cytarabine
DRUG: Idarubicin
DRUG: Quizartinib

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]